Top Markets
Coin of the day
Gwo Xi Stem Cell Applied Technology Co. , Ltd Gwo Xi Stem Cell Applied Technology Co. , Ltd

Gwo Xi Stem Cell Applied Technology Co. , Ltd

6704
株式のランク #24642
Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem... Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem cell-based therapies, addressing critical unmet medical needs in patient care. Its product pipeline currently features two pioneering autologous adipose-derived stem cell treatments: GXHPC1, which is in Phase II clinical trials for liver cirrhosis, and GXNPC1, also undergoing Phase II testing, designed for the management of chronic stroke. Further expanding its therapeutic portfolio, the company is advancing GXCPC1, an allogeneic adipose-derived stem cell therapy currently in combined Phase I/II clinical trials for osteoarthritis, alongside GXIPC1, another allogeneic fat-derived stem cell treatment in early-stage Phase I trials for diabetes. Established in 2011, the company maintains its headquarters in Zhubei, Taiwan.
株価
$0.60736143
時価総額
$58.28M
変化(1日)
-1.04%
変化(1年)
-21.09%
TW
取引 Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)

カテゴリー

Gwo Xi Stem Cell Applied Technology Co. , Ltd(6704)の利益
2026 時点の利益 TTM: 0
Gwo Xi Stem Cell Applied Technology Co. , Ltd の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Gwo Xi Stem Cell Applied Technology Co. , Ltd の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$1.61B -
AU
- -
CH